Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Silvia Mihaela IlieNathalie BriotGuillaume ConstantinNicolas RoussotAlis IlieAnthony BergeronLaurent ArnouldFrançoise BeltjensIsabelle DesmoulinDidier MayeurCourèche KaderbhaiAudrey HennequinClémentine JankowskiMarie Martine PadeanoHelène CostazAlix AmetCharles CoutantBruno CoudertAurélie BertautSylvain Ladoire

Published in: Breast cancer (Tokyo, Japan) (2023)

In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.

Keyphrases

neoadjuvant chemotherapy
early breast cancer
locally advanced
lymph node
sentinel lymph node
poor prognosis
transcription factor
rectal cancer
squamous cell carcinoma
binding protein
early stage
long non coding rna